Magenta Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Magenta Therapeutics's estimated annual revenue is currently $8.5M per year.
- Magenta Therapeutics received $52.0M in venture funding in April 2018.
- Magenta Therapeutics's estimated revenue per employee is $76,116
- Magenta Therapeutics's total funding is $305.9M.
- Magenta Therapeutics has 112 Employees.
- Magenta Therapeutics grew their employee count by 18% last year.
Magenta Therapeutics Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Magenta Therapeutics?
Magenta Therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. By creating a platform focused on key areas of transplant medicine, Magenta Therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.keywords:N/A
Number of Employees
Employee Growth %
Magenta Therapeutics News
--(BUSINESS WIRE)--Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the...
Magenta Therapeutics Inc. has cut its workforce by 14%, or about 11 people, as it scales back work on a drug for blood cancers and...
Changes in Magenta's operating procedures stem from its recent success in a Phase I/II targeted conditioning clinical trial of therapeutic MGTA-...
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors CAMBRIDGE, Mass.-(BUSINESS WIRE)- May 12, 2021-Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell trans ...
Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has agreed to sell approximately 9,600,000 shares of its common stock to certain institutional inve ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Magenta Therapeutics Funding
|2016-11-17||$48.5M||A||Third Rock Ventures, LLC||Article|